Publications

Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SNing, Oswald E et al..  2017.  BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.. Cancer Discov.

Deb D, Rajaram S, Larsen JE, Dospoy PP, Marullo R, Li L-S, Avila K, Cerchietti L, Xue F, Minna J et al..  2017.  Combination therapy targeting BCL6 and phospho-STAT3 defeats intra-tumor heterogeneity in a subset of non-small cell lung cancers.. Cancer Res.

Cerchietti L, Melnick A.  2017.  DNA Methylation-Based Biomarkers.. J Clin Oncol. :JCO2016710616.

Du W, Goldstein R, Jiang Y, Aly O, Cerchietti L, Melnick AM, Elemento O.  2017.  Effective combination therapies for B cell lymphoma predicted by a virtual disease model.. Cancer Res.

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L.  2017.  The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.. Leuk Lymphoma. :1-3.

Vu LP, Prieto C, Amin EM, Chhangawala S, Krivtsov A, M Calvo-Vidal N, Chou T, Chow A, Minuesa G, Park SMi et al..  2017.  Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells.. Nat Genet. 49(6):866-875.

Apoorva F, Tian YF, Pierpont TM, Bassen DM, Cerchietti L, Butcher JT, Weiss RS, Singh A.  2017.  Lymph Node Stiffness Mimicking Hydrogels Regulate Human B Cell Lymphoma Growth and Cell Surface Receptor Expression in a Molecular Subtype-Specific Manner.. J Biomed Mater Res A.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, M Calvo-Vidal N, Phillip J, Pera B, Yang SNing, Takpradit K et al..  2017.  THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.. Nat Commun. 8:14290.

Pera B, Tang T, Marullo R, Yang S-N, Ahn H, Patel J, Elstrom R, Ruan J, Furman R, Leonard J et al..  2016.  Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.. Clin Epigenetics. 8:79.

Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang SN, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL et al..  2016.  Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.. Blood. 127(7):858-68.

Rodina A, Wang T, Yan P, Gomes EDaGama, Dunphy MPS, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H et al..  2016.  The epichaperome is an integrated chaperome network that facilitates tumour survival.. Nature. 538(7625):397-401.

Dupéré-Richer D, Kinal M, Pettersson F, Emond A, M Calvo-Vidal N, Nichol JN, Guilbert C, Plourde D, Oros KKlein, Nielsen TH et al..  2016.  Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.. Leuk Lymphoma. :1-4.

Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang S-N, Cohen J et al..  2016.  Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.. J Clin Invest.

Dupont T, Yang SNing, Patel J, Hatzi K, Malik A, Tam W, Martin P, Leonard J, Melnick A, Cerchietti L.  2016.  Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.. Oncotarget. 7(3):3520-32.

Boi M, Todaro M, Vurchio V, Yang SNing, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M et al..  2016.  Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.. Oncotarget. 7(48):79637-79653.

Marullo R, Rutherford SC, Leonard JP, Cerchietti L.  2016.  Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.. Cell Cycle. 15(17):2241-7.

Pan H, Jiang Y, Boi M, Tabbò F, Redmond D, Nie K, Ladetto M, Chiappella A, Cerchietti L, Shaknovich R et al..  2015.  Epigenomic evolution in diffuse large B-cell lymphomas.. Nat Commun. 6:6921.

Purwada A, Jaiswal MK, Ahn H, Nojima T, Kitamura D, Gaharwar AK, Cerchietti L, Singh A.  2015.  Ex vivo engineered immune organoids for controlled germinal center reactions.. Biomaterials. 63:24-34.

Pera B, M Calvo-Vidal N, Ambati S, Jordi M, Kahn A, J Díaz F, Fang W, Altmann K-H, Cerchietti L, Moore MAS.  2015.  High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells.. Cancer Lett. 368(1):97-104.

Cayrol F, Flaque MCDiaz, Fernando TM, Yang S-N, Cerchietti L, Cremaschi G.  2015.  Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. Blood. 125(5):841-851.

Tian YF, Ahn H, Schneider RS, Yang SNing, Roman-Gonzalez L, Melnick AM, Cerchietti L, Singh A.  2015.  Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.. Biomaterials. 73:110-9.

Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A et al..  2015.  A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. Leukemia. 29(6):1390-401.

Cerchietti L, Pera B.  2015.  Personalized Epigenetic Therapy - Chemosensitivity Testing. Epigenetic Cancer Therapy. :667-676.

Goldstein RL, Yang SNing, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G et al..  2015.  Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.. J Clin Invest. 125(12):4559-71.

Walker SR, Liu S, Xiang M, Nicolais M, Hatzi K, Giannopoulou E, Elemento O, Cerchietti L, Melnick A, Frank DA.  2015.  The transcriptional modulator BCL6 as a molecular target for breast cancer therapy.. Oncogene. 34(9):1073-82.